Ind. J Physiol. Pharmac., Volume 33, Number 1, 1989

# EFFECT OF a-TOCOPHEROL ON THE MICROSOMAL LIPID PEROXIDATION INDUCED BY DOXORUBICIN : INFLUENCE OF ASCORBIC ACID

## A. GEETHA, J. CATHERINE AND C. S. SHYAMALA DEVI\*

Department of Biochemistry, A.C. College of Technology, Guindy, Madras - 600 025

#### ( Received on September 15, 1988 )

Summary :  $\alpha$ -Tocopherol (40 mg/rat/day) was administered, orally, to doxorubicin treated rats (2 mg/kg, twice weekly, for 4 weeks) singly and also in combination with ascorbic acid (1 g/100 ml/day) in drinking water. The vitamin therapy was carried out for a period of 1 month. The microsomal lipid peroxide levels in liver and heart were found to be increased in doxorubicin treated rats.  $\alpha$ -tocopherol and ascorbic acid treatment decreased the lipid peroxide level and also NADPH-dependent lipid peroxidation. A significant depletion of glutathione in liver and heart of doxorubicin treated animals was found to be ameliorated by vitamin therapy. Ascorbic acid was found to maintain the level of microsomal  $\alpha$ -tocopherol. The activities of the detoxifying enzymes like catalase, superoxide dismutase and glutathione peroxidase were suppressed in doxorubicin treated rats and vitamines coadministration maintained the levels of these enzymes. Ascorbic acid was found to potentiate the antioxidant nature of  $\alpha$ -tocopherol.

Key words : doxorubicin glutathione lipid peroxidation

a-tocopherol ascorbic acid catalase superoxide dismutase

## INTRODUCTION

Doxorubicin (adriamycin is an antitumor antibiotic isolated from cultures of streptomytes peucetius (1). This drug is effective against human malignancies such as leukemias lymphomas and many solid tumors (2). However, repetitive administration in patients and in experimental animals causes toxic side effects in liver (3) and heart (4). Various efforts have been made to overcome this toxicity, by supplementing agents which do not interfere with the cytotoxic effect of the drug. Few among them are  $\alpha$ -tocopherol, riboflavin butyrate and ubiquinone (5, 6).

The cell killing effects of doxorubicin involve intercalation into double helical DNA and subsequent inhibition of polymerases and of DNA and RNA

Corresponding Author

synthesis (7). Doxorubicin has been shown to be a potent inducer of free radicals. In vitro, quinone containing anticancer agents including doxorubicin have been shown to form semiquinone free radical intermediates in the presence of certain flavin enzymes (8). These free radicals abstract hydrogen from polyunsaturated fatty acids which are abundant in membrane phospholipids. These events can initiate a chain reaction in which there is formation of organic peroxides and production of more organic radicals, which are responsible for various deleterious effects. Among subcellular organells, microsomes are labile to lipid peroxidation and concurrent damage (9).

Fortunately, the living cell has defense mechanisms which can provide protection against devastating effects of lipid peroxidation. The most important components in the defense systems are vitamin E, glutathione and some glutathione dependent enzymes (10).

a-Tocopherol (Vit E) plays an important role as an antioxidant in microsomes along with glutathione (11) and ascorbic acid has been reported to influence the activity (12).

Since liver is the major organ involved in detoxification and heart is the target organ for this drug, we have studied the effect of the doxorubicin and vitamins on liver and heart microsomes.

## MATERIAL AND METHODS

Chemicals: Doxorubicin hydrochloride, bovine serum albumin, NADPH and 1, 1, 3, 3—tetramethoxypropane (Sigma Chemical Company, Missouri), ascorbic acid, sodium pyrophosphate, ferric chloride and potassium chloride (all from E. Merck; analytical grade) were used.

Methods: Adult male Wistar rats were maintained with free access to food and water. The rats were divided into 4 groups. Group I served as control. Group II, III and IV animals received doxorubicin (2 mg/kg, iv) in saline, twice weekly, for 4 weeks (13). Group II animals were left without vitamin therapy. Group III animals were given Vit. E orally (400 mg/kg) and Group IV animals were given ascorbic acid in drinking water] (1 g/100 ml/day) along with vit E. The vitamin therapy was carried out for a period of 30 days.

After the experimental period the animals were killed by cervical decapitation. Liver and heart were removed washed in ice-cold saline and homogenised in isotonic potassium chloride. A portion of the homogenate was used for the estimation of GSH (14). GSH peroxidase (15), GSHreductase (16), GSH transferase (17), catalase (18) and superoxide dismutase (19). Microsomes were separated by differential centrifugation (20) from the remaining portion of the homogenate. The lipid peroxide level was determined by the method of Okhawa *et al* (21). NADPH dependent lipid peroxidation was measured by the method of Hogberg *et al* (22). The method of Tayler *et al* (23) was adopted for the estimation of vit E in microsomes. Protein was estimated by the method of Lowry *et al* (24).

#### **RESULTS AND DISCUSSION**

Levels of microsomal lipid peroxides in liver and heart of control and test animals are given in Table I.

TABLE I : Levels of microsomal lipid peroxides in liver and heart of control and doxorubicin treated animals with or without vitamin supplementation. Values are expressed as mean  $\pm$  SD from 6 animals in each group.

Animals treated with	Liver	Heart	
I. None	500.0±43.3	220.0±11.1	
II. DXR	750.1±31.4 <sup>@</sup>	363.1±14.0 <sup>@@</sup>	
III. DXR+a-toc	573.9±41.5 <sup>@</sup>	300.4±17.1 <sup>@</sup>	
IV. DXR+a-toc+asc	300.2±21.5 <sup>@@</sup>	150.0±11.9 <sup>@@</sup>	

Lipid peroxide levels are expressed as n moles of MDA formed/100 mg protein

 $^{@}P < 0.01$   $^{@@}P < 0.001$ 

#### Group I is compared with Group II Group III & IV are compared with Group II

A significant increase in the level of lipid peroxides is noted in doxorubicin treated animals. Singal *et al* (25) have also demonstrated that lipid peroxide production is enhanced during doxorubicin treatment. But the percentage of increase is high in heart when compared to liver. This could be due to the lesser availability of antioxidants in heart (26). Vitamin E treatment reduced the level of lipid Ind. J. Physiol. Pharmac., Volume 33, Number 1, 1989

peroxides significantly. The protection given by Vit E is potentiated by the supplementation cf vitamin C (Group IV).

TABLE II : Effect of doxorubicin and vitamins on NADPHdependent microsomal lipid peroxidation.Values are expressed as Mean ± S.D. from6 animals in each group.

Animals treated with	Liver	Heart
I. None	703.4±40.0	285.0±21.0
II. DXR	1120.0±83.1 <sup>@</sup>	724.3±69.0 <sup>@</sup>
III. DXR+a-toc	875.1±64.0 <sup>@</sup>	550.5±31.0 <sup>@</sup>
IV. $DXR + \alpha - toc + asc$	601.5±49.0 <sup>@@</sup>	325.0±29.0 <sup>@@</sup>

The level of lipid peroxidation is expressed in terms of n moles MDA Formed/100 mg protein/5 min

<sup>(a)</sup> P < 0.01; <sup>(a)</sup> (a) P < 0.001

Group I is compared with Group II

Group III & IV are compared with Group II

Table II shows a significant increase (0.01) in NADPH dependent lipid peroxidation in doxorubicin treated animals. The microsomal metabolism of the drug may be by two major pathways, one pathway consists of the reductive cleavage of the sugar moiety to yield anthraquinone aglycone. It involves a semiquinone free radical intermediate produced by Cyt-P450 reductase which is mediated by NADPH (27). Bachur et al (28) have also demonstrated the oxidation of NADPH during doxorubicin metabolism. The NADPH dependent increase in lipid peroxide level clearly shows the possibility of the production of toxic free radicals during microsomal metabolism of the drug. An effective decrease in the NADPH induced lipid peroxide level is noted in group III and IV animals. This could be either due to the antioxidant effect of these vitamins or the interaction in the NADPH Cyt-P450 reductase based metabolism of the drug.

Fig. 1 shows the level of Vit. E in microsomal fractions of liver and heart of control and test




Fig. 1 : Vitamin E levels in microsomal fractions of liver and heart of rats. Group I : control, Groups II, III and IV, doxorubicin treated. Groups III and IV were given Vit. E, Group IV was also given Vit. C (See Methods).

#### 56 Geetha et al.

Ind. J. Physiol. Pharmac., Volume 33, Number 1, 1989

animals. Group III and IV animals which were treated with vitamins show high level of microsomal Vit. E content which is responsible for the low level of lipid peroxides noted in our results (Table I). It has been demonstrated that Vit. E protects the microsomes from peroxidative damage with the combined action of glutathione (11). A greater increase in the Vit. E content of group IV animals when compared with group III might have been due to the regeneration of a-tocopherol by ascorbic acid. It has been reported that Vit C regenerates a-tocopherol from tocopheroxyl radical (12) which is produced during its antioxidant action.

The level of glutathione and the activities of glutathione dependent enzymes are given in Table III and IV. A significant decrease in GSH content is seen in doxorubicin treated animals. Increased consumption of GSH could be due to the interaction with toxic hydroperoxides formed during lipid peroxidation (29) however, vitamins treatment maintains the level of glutathione. It has been proved that vit, E along with cytosolic GSH protects microsomes from lipid peroxidation damage (11).

peroxidase activity decreases Glutathione considerably in doxorubicin treated rats (Group II) which could be due to the inactivation of the enzyme by free radicals (30). The activity of cytosolic glutathione peroxidase which protect microsomes (31) is restored in animals given vitamin therapy.

The activities of GSH-reductase and GSHtransferase which provide continuous supply of GSH, increases significantly in vitamins supplemented animals.

Animals treated with	GSH (n mole g tissue)		GSH Peroxidase (% of control)	
	Liver	Heart	Liver	Heart
I. None	6.98±0.21	4.00±0.31		
II. DXR	3.52±0.20 <sup>@</sup>	1.52±0.50 <sup>@</sup>	70.1±5.1 <sup>@</sup>	61±2.3
III. DXR + α-toc	5.62±0.35 <sup>@</sup>	3.15±0.10 <sup>@</sup>	92.8±8.1	84±3.1
IV. DXR + $\alpha$ -toc + asc	7.10±0.51 <sup>@@</sup>	5.03±0.31 <sup>@@</sup>	110.0±8.3 <sup>@@</sup>	93±7.1@

TABLE III : Effect of doxorubicin and vitamins of the level of reduced glutathione and the activity of glutathione peroxidase. Values are expressed as Mean  $\pm$  SD from 6 animals in each group.

Group I is compared with Group II

Group III & IV are compared with Group II

#### Ind. J. Physiol Pharmac., Volume 33, Number 1, 1989

Table V shows the activities of catalase and superoxide dismutase in liver and heart of experimental animals. These two enzymes are effectively involved in scavenging hydroxyl and superoxide anion radicals (32). Depletion of catalase and SOD activities may accordingly lead to an increase in lipid peroxide level in group II animals. The enzyme activities are restored in vitamins treated animals probably by the alternative utilization of other antioxidants like Vit E and glutathione.

 TABLE IV : Effect of doxorubicin and vitamins on GSH-reductase and GSH-transferase activities.
 Values are expressed as Mean±S.D. from 6 animals in each group.

Animals treated with	GSH-reductase (% of control)		GSH-transferase (% of control)	
	Liver	Heart	Liver	Heart
II. DXR	66±3.1 <sup>@</sup>	70±5.1 <sup>@</sup>	70±3.1 <sup>@</sup>	49±3.5 <sup>@@</sup>
III. DXR + α-toc	92±6.1 <sup>@</sup>	86±5.2 <sup>@</sup>	99±4.3 <sup>@</sup>	64±5.1@
IV. DXR $+ \alpha$ -toc $+ asc$	119±7.1 <sup>@@</sup>	101±5.1@@	131±7.1@@	98±4.9 <sup>@</sup>

<sup>(a)</sup> P < 0.01 <sup>(a)</sup> (a) P < 0.001

Group I is compared with Group II

Group III & IV are compared with Group II

TABLE V : Effect of doxorubicin and vitamins on the activities of catalase and superoxide dismutase. Values are expressed as Mean±SD from 6 animals in each group.

Animals treated with	Catalase m mole H2O2 decomposed/mg protein		Superoxide dismutase units/mg protein	
	Liver	Heart	Lever	Heart
I. None	15.01±0.80	5.1±0.1	8.12±0.25	2.12±0.15
II. DXR	9.10±0.61 <sup>@</sup>	2.9±0.1 <sup>@</sup>	5.00±0.31 <sup>@</sup>	1.05±0.08 <sup>@</sup>
III. DXR + α-toc	13.01±0.50 <sup>@</sup>	5.5±0.2 <sup>@</sup>	6.94±0.41 <sup>@</sup>	1.98±0.07 <sup>@</sup>
IV. DXR + $\alpha$ -toc + asc	19.20±0.91 <sup>@@</sup>	7.2±0.5 <sup>@@</sup>	10.79±0.51 <sup>@@</sup>	2.23±0.02 <sup>@</sup>

<sup>@</sup> P < 0.01 <sup>@</sup><sup>@</sup> P < 0.001

Group I is compared with Group II Group II & IV are compared with Group II 58 Geetha et al.

Hence, it is concluded that Vit E supplementation provides beneficial effects against doxorubicin induced toxicity and ascorbic acid potentiates the role of Vit E as an antioxidant.

#### ACKNOWLEDGEMENTS

One of the authors (AG) thanks the Council of Scientific and Industrial Research, New Delhi, for financial support.

#### REFERENCES

- Arcamone F, Franceschi G, Penco S, Selva A. Adriamycin (14-hydroxy daunomycin) an antitumor antibiotic. *Tetrahedron Lett* 1969; 13:1007-1010.
- Carter SK. Adriamycin-a review. J Natn Cancer Inst 1975: 55:1265-1270.
- Benzamine RS, Wiernik PH and Bachur NR. Adriamycinchemotheraphy-Efficacy, safety and pharmacologic basis of an intermittent single high dosage schedule. *Cancer* 1974; 33:19-27.
- 4. Rinehart J J, Lewis RP and Balcerak SP. Adriamycin cardiotoxicity in man. Ann Int Med 1974; 91:475-478.
- Ogura R, Toyama H and Katsuki K. Effect of vitamins to the mitochondrial disorders induced by lipid peroxide formation. *Bitamin* 1979; 53 (12):569-76.
- Vanvlcet JR, Greenwood L, Ferrans VJ and Rebar AH. Effect of selenium-Vit. E on adriamycin induced cardiomyopathy in rabbits. Am J Vet Res 1978; 39:997-1010.
- Momparler RL, Karon M, Siegel SE and Avila F. Effect of adriamycin on DNA, RNA and protein synthesis in cell free systems and intact cell. *Cancer Res* 1976; 36: 2891-2995.
- Doroshow JH. Effect of anthracyclin antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43:460-472.
- Victoria EJ and Barber AA. Peroxydation of microsomal membrane protein-lipid complexes. Lipids 1969; 4:582-588.
- Fridovich I. In Pryer WA. Free radicals in biology New York Academic press, Vol. I, 1976; 239-250.
- 11. Haenen GRMM and Bast A. Protection against lipid peroxidation by a microsomal glutathione dependent labile factor. FEBS Lett 1983; 159:24-28.
- Packer JE, Slater TF and Willson RL. Reactions of the CCI<sub>4</sub>-related peroxy free radicals with amino acids. *Nature* 1979; 298.737-738.
- Adi P, William C and John M. Effect of tetracyclin on ADM Cardiomyopathy, 1981; 7 (4-5):379-382.
- Thomas G and Skrinska V. Determination of glutathione in human platelets. Clin Chem 1985; 31:350-352.
- Paglia DE and Valentine WN. Characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1: 67; 70:158-169.
- 16. Pinto PE and Bartley. The effect of age and sex on glutathione reductase and glutathione peroxidase activities and on aerobic glutathione oxidation in rat liver homogenate. Biochem J 1969; 112:109-115.
- Habig WH, Pabst MJ and Jakoby WB. Glutathione-S. transferases. J Biol Chem 1974; 249:7130-7139.
- Beers RF (Jr) and Sizer IV. A spectrophotometric method for measuring the breakdown of H<sub>2</sub>O<sub>2</sub> by catalase. *J Biol Chem* 1952; 195:133-140.

- Marklund S and Marklund. Involvement of the superoxide anion radical in the antioxidation of pyrogaliol and a convenient method for superoxide dismutase. Eur J Biothem 1974; 47:469-474.
- Klein SM, Cohen G, Leiber CS and Cederbaum AI. Increased microsomal oxidation of hydroxyl radical scavening agents and ethanol after chronic consumption of ethanol. Arch Biochem Biophys 1983; 223:425-432.
- Ohkawa H, Ohishi N and Yagi K. Reaction of linoleic acid hydroperoxide with thiobarbituric acid. Anal Biochem 1979; 95:351-354.
- Hogberg J, Larson RE, Kristoferson A and Orrhenius S. NADPH-dependent reductase solubilised from microsomes by peroxidation and its activity. Biochem Biophys Res Commun 1974; 56:836-840.
- Tayler SL, Lambden MP and Tappel AL. Sensitive flourimetric method for tissue tocopherol analysis. *Lipids* 1976; 11:530-538.
- Lowry OH, Rosebrough NJ, Farr LA and Randall RJ. Protein measurement with Folin phenol reagent. *J Biol* Chem 1951; 193:265-275.
- 25. Singal PK, Segstro RJ, Singh RR and Kutryk MJ. Changes in lysosomal morphology and enzyme activities during the development of adriamycin induced cardiomyopathy. Can J Cardiol 1985; 1:139-147.
- Honegger HP. Cited by Porumb H. and Petrescu I. Interaction with mitochondria of the anthracycin cytostatics adriamycin and daunomycin. Prog Biophys mol Pathol 1986; 48:103-125.
- Sinha BK, Trush MA, Kennedy KA and Minmangh EG. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 1984; 44:2892-2896.
- Bachur NR, Gordon SL and Gee MV. Anthracyclin antibiotic augmentation of microsomal electron transport and free radical formation. *Mol Pharmacol* 1977; 901-910.
- Condall AR and Tappel ALL. Evidence for suitability of glutathione peroxidase as a protective enzyme: Studies of oxidative damage, renaturation and proteolysis. Arch Biochem Biophys 1983; 223:407-416.
- Schaick KM. Free radical initiation in protein and amino acids by ionising and UV radiation and lipid oxidation. U. S. Environ. Prot. Agency off Res Dev. EPA 1981; 600/9-81 001:91-125.
- 31. Ursini FM, Mriorino M, Valente M, Ferri L and Gregolin C. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity. Biochim Biophys Acta 1982; 710:197-211.
- Sinet PM and Garler G. Inactivation of Cu-Zn superoxide dismutase during exposure to superoxide radical and hydrogen peroxide. Arch Biochem Biophys 1981: 212:411-416.